$7.28 Million is the total value of Consonance Capital Management LP's 2 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 71.4% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
SURROZEN INC | $7,065,000 | -32.7% | 3,497,500 | 0.0% | 97.05% | +119.3% | ||
SURROZEN INC*w exp 08/01/203 | $215,000 | -3.6% | 1,165,832 | 0.0% | 2.95% | +214.1% | ||
TNDM | Exit | TANDEM DIABETES CARE INC | $0 | – | -4,294 | -100.0% | -1.07% | – |
GMED | Exit | GLOBUS MED INCcl a | $0 | – | -5,405 | -100.0% | -1.28% | – |
UTHR | Exit | UNITED THERAPEUTICS CORP DEL | $0 | – | -2,998 | -100.0% | -2.98% | – |
CMPX | Exit | COMPASS THERAPEUTICS INC | $0 | – | -1,603,789 | -100.0% | -17.79% | – |
SLN | Exit | SILENCE THERAPEUTICS PLCads | $0 | – | -634,270 | -100.0% | -31.70% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-14
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
UNITED THERAPEUTICS CORP DEL | 29 | Q2 2022 | 15.9% |
ADMA BIOLOGICS INC | 27 | Q4 2020 | 2.3% |
RETROPHIN INC | 23 | Q1 2020 | 11.3% |
ANI PHARMACEUTICALS INC | 23 | Q3 2019 | 7.9% |
VERICEL CORP | 21 | Q4 2019 | 5.5% |
AMARIN CORP PLC | 14 | Q3 2019 | 14.4% |
GLOBUS MED INC | 13 | Q2 2022 | 24.7% |
ORTHOFIX INTL N V | 13 | Q3 2016 | 9.7% |
PACIFIC BIOSCIENCES CALIF IN | 13 | Q4 2018 | 9.7% |
CATALYST PHARM PARTNERS INC | 13 | Q3 2019 | 9.4% |
View Consonance Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
Surrozen, Inc./DESold out | December 15, 2022 | 0 | 0.0% |
ADMA BIOLOGICS, INC. | February 14, 2022 | 1,289,481 | 1.4% |
ASSEMBLY BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
CASI Pharmaceuticals, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
Cellectar Biosciences, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
Gamida Cell Ltd.Sold out | February 14, 2022 | 0 | 0.0% |
GenMark Diagnostics, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
Protagonist Therapeutics, IncSold out | February 14, 2022 | 0 | 0.0% |
Sio Gene Therapies Inc.Sold out | February 14, 2022 | 0 | 0.0% |
Consonance-HFW Acquisition Corp. | April 27, 2021 | 1,000,000 | 10.4% |
View Consonance Capital Management LP's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
4 | 2022-12-15 |
SC 13D/A | 2022-12-15 |
13F-HR | 2022-11-14 |
13F-HR | 2022-08-15 |
13F-HR | 2022-05-16 |
13F-HR | 2022-02-14 |
SC 13G/A | 2022-02-14 |
SC 13G/A | 2022-02-14 |
SC 13G/A | 2022-02-14 |
SC 13G/A | 2022-02-14 |
View Consonance Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.